CAFC overturns $1.2 billion damages in another Section 112 blow for biotech genus IP

Juno Therapeutics and its partner Sloan Kettering Memorial Cancer Center lose out after the Federal Circuit invalidates a key patent under written description rules

Get unlimited access to all IAM content